The purpose of this guidance is to assist sponsors in the clinical development of drugs for the treatment of gastroesophageal reflux disease (GERD) in the pediatric population, encompassing infants, children, and adolescents. Specifically, this guidance addresses the Food and Drug Administration’s (FDA’s) current thinking regarding clinical presentation by age and disease, study populations, endpoints, and clinical pharmacology issues affecting dosing. This draft guidance is intended to serve as a focus for continued discussions among the Division of Gastroenterology and Inborn Errors Products, pharmaceutical sponsors, the academic community, and the public.